Japan's Ministry of Health, Labour and Welfare expanded the eligible population for GSK's RSV vaccine Arexvy to include adults aged 18 to 49 at increased risk for RSV disease. The decision broadens the addressable market for the vaccine in Japan and supports GSK's respiratory franchise. The news is favorable for GSK but is unlikely to move the broader market.
Japan's Ministry of Health, Labour and Welfare expanded the eligible population for GSK's RSV vaccine Arexvy to include adults aged 18 to 49 at increased risk for RSV disease. The decision broadens the addressable market for the vaccine in Japan and supports GSK's respiratory franchise. The news is favorable for GSK but is unlikely to move the broader market.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
